Table 1.
Patient characteristics
| Characteristic | Total | No NAFLD | NAFLD | P value |
|---|---|---|---|---|
| (n = 218) | (n = 83) | (n = 135) | ||
| Male (n, %) | 142 (65.1%) | 55 (66%) | 87 (64%) | 0.784 |
| Age (years) | 63.8 ± 10.5 | 62.2 ± 11.4 | 64.8 ± 9.8 | 0.084 |
| BMI (kg/m2) | 26.3 ± 3.8 | 25.0 ± 3.5 | 27.1 ± 3.7 | <0.001 |
| ASA classification (n, %) | ||||
| 1 | 35 (16.1%) | 13 (16%) | 22 (16%) | 0.491 |
| 2 | 132 (60.6%) | 47 (56%) | 85 (63%) | |
| ≥3 | 51 (23.4%) | 23 (28%) | 28 (21%) | |
| Comorbidity (n, %) | 134 (62%) | 46 (55%) | 88 (65%) | 0.150 |
| Cardiovascular | 97 (45%) | 33 (40%) | 64 (47%) | 0.270 |
| Pulmonary | 21 (10%) | 9 (11%) | 12 (9%) | 0.635 |
| Renal | 7 (3%) | 4 (5%) | 3 (2%) | 0.431 |
| Diabetes mellitus | 19 (9%) | 3 (3.6%) | 16 (12%) | 0.036 |
| Other | 21 (10%) | 8 (10%) | 13 (10%) | 0.998 |
| Neoadjuvant chemotherapy (n, %) | 150 (69%) | 58 (69%) | 92 (68%) | 0.789 |
| Radical resection (n, %) | 145 (67%) | 59 (71%) | 86 (64%) | 0.262 |
| Fong‐score > 2 (n, %) | 72 (33%) | 26 (31%) | 46 (34%) | 0.675 |
| Synchronous metastasis (n, %) | 71 (33%) | 51 (61%) | 96 (71%) | 0.139 |
| Node positive primary (n, %) | 140 (64%) | 53 (64%) | 87 (64%) | 0.930 |
| Largest metastasis ≥ 5 cm (n, %) | 29 (13%) | 13 (16%) | 16 (12%) | 0.421 |
| >1 metastasis (n, %) | 128 (59%) | 47 (57%) | 81 (60%) | 0.623 |
| CEA ≥ 200 ng/mL (n, %) | 6 (3%) | 2 (2%) | 4 (3%) | 1.000 |
| Liver steatosis grade (n, %) | ||||
| 0 | 83 (38%) | 83 (100%) | — | <0.001 |
| 1 | 106 (48%) | — | 106 (78%) | |
| 2 | 21 (10%) | — | 21 (16%) | |
| 3 | 8 (4%) | — | 8 (6%) | |
| Tissue L3‐index (Z‐score) | ||||
| Muscle | 0 ± 1.0 | −0.20 ± 0.91 | 0.12 ± 1.00 | 0.022 |
| VAT | 0 ± 1.0 | −0.46 ± 0.91 | 0.28 ± 0.93 | <0.001 |
| SAT | 0 ± 1.0 | −0.30 ± 0.89 | 0.18 ± 1.00 | <0.001 |
| TAT | 0 ± 1.0 | −0.42 ± 0.92 | 0.26 ± 0.94 | <0.001 |
| Tissue radiation attenuation (Z‐score) | ||||
| Muscle | 0 ± 1.0 | 0.03 ± 1.05 | −0.02 ± 0.96 | 0.752 |
| VAT | 0 ± 1.0 | 0.43 ± 1.07 | −0.27 ± 0.83 | <0.001 |
| SAT | 0 ± 1.0 | 0.32 ± 1.22 | −0.20 ± 0.75 | 0.001 |
| ΔTissue L3‐index (%/100 days) a | ||||
| Muscle | −2.4 ± 9.7 | −1.5 ± 9.4 | −2.9 ± 9.9 | 0.425 |
| VAT | 10.4 ± 43.3 | 20.8 ± 60.2 | 3.7 ± 26.1 | 0.060 |
| SAT | 3.6 ± 20.2 | 7.4 ± 25.3 | 1.1 ± 15.8 | 0.114 |
| TAT | 5.1 ± 22.6 | 10.4 ± 30.6 | 1.7 ± 14.9 | 0.065 |
| ΔTissue radiation attenuation (%/100 days) a | ||||
| Muscle | 5.7 ± 23.3 | 6.3 ± 25.5 | 5.3 ± 21.9 | 0.801 |
| VAT | 1.2 ± 7.5 | 1.4 ± 9.3 | 1.1 ± 6.1 | 0.859 |
| SAT | 1.4 ± 7.8 | 1.5 ± 9.4 | 1.4 ± 6.7 | 0.948 |
Patient characteristics and differences in characteristics between non‐NAFLD and NAFLD patients. Continuous variables are depicted as mean ± standard deviation.
ASA, American Society of Anaesthesiologists; BMI, body mass index; CEA, carcinoembryonic antigen; NAFLD, non‐alcoholic fatty liver disease; SAT, subcutaneous adipose tissue; TAT, total adipose tissue; VAT, visceral adipose tissue.
a
Differences in body composition over time were assessed in 131 patients.